Article

Phase II trial of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin in elderly transplant-ineligible patients with relapsed/refractory peripheral T- cell lymphoma

2023-12-04

Abstract excerpt

<title>Abstract</title> <p>Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. The objective of this study was to characterize the safety and efficacy of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin (GDP) therapy (GDPR). This study of patients treated betwee...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fbdb8b69-f6dd-5867-9bd1-ae6ba9b5c763
DOI: 10.21203/rs.3.rs-3685901/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin in elderly transplant-ineligible patients with relapsed/refractory peripheral T- cell lymphomaDOI 10.21203/rs.3.rs-3685901/v1Read

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomasSemantic proximity Read

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.Semantic proximity Read

Histone Deacetylase Inhibitors for Peripheral T-cell Lymphomas: From Biology to Real-World TherapySemantic proximity Read

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in ChinaSemantic proximity Read

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative dataSemantic proximity Read

Romidepsin for the treatment of cutaneous T-cell lymphomaSemantic proximity Read

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphomaSemantic proximity Read

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumorsSemantic proximity Read

First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantationSemantic proximity Read

Phase I study of vorinostat in combination with standard <scp>CHOP</scp> in patients with newly diagnosed peripheral T‐cell lymphomaSemantic proximity Read

Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.Semantic proximity Read

BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation FeasibilitySemantic proximity Read